BDCA-2 stimulation inhibits interferon production, and it has been proposed as a therapeutic target in different pathologies linked to high levels of type I interferon, such as Systemic lupus erythematosus (SLE) (Reily et al, 2019). This evidence concerns the gene CLEC4C and systemic lupus erythematosus.